2.82 USD
▼+0.04-5.37%
盘后 2.97 -0.34%
2026-08-03
市值
$125.23M
市盈率
—
EPS
-0.85
股息率
—
52 周区间
2.29 – 8.54
成交量
787.20K
Beta
0.57
目标价
17.50
52W 低 2.2952W 高 8.54
价格走势
公司简介
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product...